Monoetl phthalate-d4 is the deuterium labeled Monoetl phthalate[1]. Monoetl phthalate is a metabolite of dietl phthalate. Monoetl phthalate acts as a urinary biomarker of phthalates exposure indicating the risks of troid cancer and benign nodule[2][3].
Stable heavy isotopes of drogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
[2]. Chong Liu, et al. Urinary biomarkers of phthalates exposure and risks of troid cancer and benign nodule. J Hazard Mater. 2020 Feb 5;383:121189.
[3]. Celal GÜven, et al. Low dose monoetl phthalate (MEP) exposure triggers proliferation by activating PDX-1 at 1.1B4 human pancreatic beta cells. Food Chem Toxicol. 2016 Jul;93:41-50.